Kornimate/medical-research-clean huggingface dataset:
rt plus egfr-tki for wild-type nsclc

Conditions: Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

Summary: concurrent chemoradiotheray is the standard care for patients with locally advanced non-small cell lung cancer (nsclc), but often accompanying with high toxicity and poor tolerability. radiosensitization of epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tki) has been proved in preclinical studies, and the safety of tki combined with thoracic radiotherapy has also been evaluated in several phase ii trials. the aim of study is to investigate the efficacy and safety of thoracic radiotherapy combined with tki in wild-type egfr patients who refused or unsuitable for concurrent chemoradiotherapy.


Eligibility criteria:
inclusion criteria: 1. nsclc confirmed by histopathology or cytology; 2. stage iia - iv nsclc ,unresectable and could not tolerate chemoradiotherapy; 3. has measurable lesion \[according to response evaluation criteria in solid tumors (recist) 1.1, must have at least one evaluable lesion with the longest dimension \>= 10mm; if the evaluable lesion is lymph node, the shortest dimension should be measured and \>=15mm\]; 4. eastern cooperative oncology group (ecog) performance status (ps) 0-1; 5. expectancy life \>= 3 months; exclusion criteria: 1. had systemic anit-nsclc treatments; 2. had be treated by her-targeting agents; 3. had local radiotherapy for nsclc; 4. has upper gastrointestinal physiological disorders, or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer; 5. diagnosed other malignant tumor besides nsclc within 5 years prior the study treatment (except having simple surgical resection with 5-year disease free survival, cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder epithelial tumor); 6. any evidence to indicate moderate or severe chronic obstructive pulmonary disease (copd); 7. known hypersensitivity to egfr-tki agents or relevant components in the formulation; 8. uncontrolled eye inflammation or infection, or any potential circumstances lead to eye inflammation or infection; 9. pregnancy or breast-feeding women; 10. ingredients mixed with small cell lung cancer patients; 11. evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.

Keywords: non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki) radiotherapy wild type
a comparison of the 15 and 30 acquisition angle breast tomosynthesis mammography for breast abnormalities

Conditions: Breast Cancer

Summary: the purpose of this study is to conduct an initial investigation into whether an alternative method of using 3d imaging might offer accurate diagnostic performance at a reduced patient radiation exposure in comparison to conventional 2d screening and diagnostic mammography and conventional 2d + 3d imaging methods.


Eligibility criteria:
inclusion criteria: * subject is female of any race and ethnicity * subject is at least 40 years old * the screening and diagnostic mammograms were performed at the recruiting institution on a hologic selenia system * subject is categorized as bi-rads 0 because if mass, density, or calcifications detected on the basis of screening or diagnostic mammography * subject will undergo study imaging within 30 days of standard of care imaging exclusion criteria: * patients who are pregnant or think they may be pregnant * patients who are breast feeding * subjects unable or unwilling to undergo informed consent * subjects with breast implants

Keywords: breast cancer tomosynthesis 3d mammogram diagnostic mammogram
risk factors for recurrence after pelvic reconstruction

Conditions: Pelvic Organ Prolapse

Summary: 232 women underwent transvaginal mesh repair (tvm)with /without transvaginal hysterectomy for symptomatic pop, including group a（accepted herniamesh polypropylene mesh， 117 patients)；group b （underwent biological graft of cook，115 patients)；follow-ups for six months and one year after the surgery and a questionnaire about the life habits associated with relapse.

we prospectively study a total of 232 women who underwent transvaginal mesh repair (tvm)with /without transvaginal hysterectomy for symptomatic pop, the patients into two groups :group a was accepted herniamesh polypropylene mesh(117)；group b underwent biological graft of cook(115)；each patient underwent an interview that included a pop-q which was quantified according to the pelvic organ prolapse quantitation (popq) system;follow-ups for six months and one year after the surgery and a questionnaire about the life habits associated with relapse.

Eligibility criteria:
inclusion criteria: 242 postmenopausal patients with primary prolapse of the anterior vaginal wall or concomitant uterine prolapse,that was stage ⅲ or higher (according to the pelvic organ prolapse quantification \[pop-q\] system). exclusion criteria: pelvic floor repair surgery history and recurrent patients ; pelvic cancer and radiation to the pelvic area in the previous 6 months; simple uterine prolapse; combined with severe stress urinary incontinence or overactive bladder (oab); local or systemic conditions that would preclude surgery or affect healing such as restricted leg motion (inability to conform to the lithotomy position) ; vaginal bleeding; infection; coagulation disorders; uncontrolled hypertension and diabetes mellitus;

Keywords: pelvic organ prolapse vaginal mesh biological graft recurrence
gps: adaptation trial of an hiv prevention counselling program for hiv-positive and hiv-negative gay and bisexual men

Conditions: HIV/AIDS; Sexually Transmitted Infection; Health Behavior

Summary: gps is a sexual health promotion and hiv prevention peer-delivered counselling program. the gps program has 4 parts: information provision about hiv and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care. the adaptation grant has three goals: 1) to establish a multi-region and multi-sectoral team that can deliver the revised program across a variety of settings, 2) to learn how best to deliver this program as individual counselling program and also how to adapt this program for hiv-negative msm, and 3) to pilot the individual program in 5 settings across ontario and british columbia. the research team will evaluate the pilot adaptation through mixed methods, employing a quantitative questionnaire and one-on-one semi-structured interviews.


Eligibility criteria:
inclusion criteria: * aged 18 years or older * self-identify as a man * self-identify as gay, bisexual, queer, same-gender-loving, or a man who has sex with men * report having engaged in condomless anal sex in the last 3 months * able to speak, read, and aurally comprehend english * depending on the study site, report hiv-negative or hiv-positive status

Keywords: hiv prevention sexual health motivational interviewing information-motivation-behavioural skills model health promotion
differential efficacy of supportive and interpretative psychodynamic techniques for dependent and self-critical depressive patients

Conditions: Major Depressive Disorder

Summary: post-hoc analysis of psychotherapy outcome data suggest that psychodynamic techniques for major depressive disorder are differentially efficacious dependent on personality traits of the patient. more specifically, supportive techniques are hypothesized to be more efficacious for dependent patients, interpretative techniques to be more efficacious for self-critical patients, and mixed supportive/interpretative techniques to be more efficacious for mixed dependent/self-critical patients. moreover, supportive techniques are hypothesized to impact on depressive symptoms through increased relational capacities while interpretative techniques impact through increased self-understanding. these hypotheses are tested in an experimental single case design with three dependent, three self-critical and three mixed dependent/self-critical depressive patients. these patients go through a time-limited (50 sessions) experimental treatment which exists of a sequence of four a phases (control conditions), one b phase (supportive techniques only), one c phase (interpretative techniques only), and one bc phase (mixed supportive/interpretative techniques).


Eligibility criteria:
inclusion criteria: * patient meets criteria for major depressive disorder (as assessed by scid-i and dsm-iv-tr) * patient is prepared to give informed consent exclusion criteria: * patient uses antidepressant medication during the treatment * patient scores 3 on the suicide item of the bdi-ii * patient meets criteria for psychotic or personality disorder (as assessed by scid-ii)
speech pattern evaluation and analysis for knowledge of ad

Conditions: Wisconsin Alzheimer's Disease Research Center; Wisconsin Registry for Alzheimer's Prevention

Summary: the goal of this observational study is to validate changes in speech as a measure of cognition in individuals at increased risk of alzheimer's disease and related dementias (adrd). this study aims to clarify how speech may be affected by alzheimer's disease. participants will complete speech collection sessions and a survey at home using an ipad. participants can expect to be in the study for 3 years.

digital technology, including recorded speech, has the capability of providing a wealth of information about early changes to cognition and communication associated with developing alzheimer's disease pathology, with the potential for highly accessible, yet low-burden measurement. in this project, researchers will recruit a subset of participants from two longitudinal, observational cohort studies enriched for individuals at risk for or living with alzheimer's disease to record their speech at home with a mobile device, longitudinally. our interdisciplinary team will then validate digital markers across all stages of alzheimer's disease and related dementias (adrd), including the prodromal phase, and can enhance sensitivity and specificity of speech metrics while contributing valuable information about remote, noninvasive, and accessible assessment and disease monitoring.

Eligibility criteria:
inclusion criteria: * must be enrolled in the wisconsin alzheimer's disease research center (w-adrc) clinical core or impact studies, or in the wisconsin registry for alzheimer's prevention (wrap) * cognitively unimpaired or have a diagnosis of mild cognitive impairment (mci) * ages 40-80 years * completion of a w-adrc or wrap study visit within the past or upcoming 12 months * have provided w-adrc or wrap with blood plasma alzheimer's disease exclusion criteria: * not actively enrolled in w-adrc or wrap * diagnosis of dementia * impaired capacity or unwilling to consent * major neurological conditions * speech disorders
evaluation of patients with refractory dermatomyositis using [18f] fapi-74 pet/mri imaging

Conditions: Refractory Dermatomyostitis

Summary: this study proposes the use of a pet isotope, \[18f\]-fibroblast activation protein inhibitor-74, for a prospective single-center, single-arm study using mri imaging for participants with refractory dermatomyostitis.


Eligibility criteria:
inclusion criteria: 1. patients with suspected dermatomyositis. 2. patient must be \> 18 years old. 3. be willing and able to provide written informed consent for the trial. exclusion criteria: 1. women who are pregnant or potentially pregnant per the department of radiology policy on imaging in potentially pregnant and pregnant women. 2. contraindication to mri or inability to lie flat for 30 min 3. any serious medical condition that in the opinion of principal investigator could pose significant risk of harm or injury to the patient if they participate in the study
tislelizumab and radiotherapy for recurrent cervical cancer

Conditions: Recurrent Cervical Carcinoma; Metastatic Cervical Carcinoma; Persistent Cervical Carcinoma; Radiotherapy; Immunotherapy; Anti-programmed Cell Death Receptor 1; Immune Checkpoint Inhibitors; Tislelizumab; Objective Response Rate; Survival Outcomes

Summary: this study is a prospective, multicenter, phase ii clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel plus bevacizumab for platinum-resistant recurrent epithelial ovarian cancer. patients with platinum-resistant recurrent ovarian cancer who meet the inclusion criteria, and don't meet any of the exclusion criteria, are enrolled in the study. they will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. the total treatment periods are no more than 6 cycles. treatment continue until disease progression, intolerable toxicity, or patient refusal. objective response rates primary objective. progression-free survival, overall survival, and safety are secondary objectives. the study will enroll a total of 50 patients.


Eligibility criteria:
inclusion criteria: 1. the patient voluntarily participates and signs informed consent 2. aged 18 years of age or older 3. has an eastern cooperative oncology group (ecog) performance status ≤ 2 within 7 days prior to the first dose of study treatment 4. has recurrent cervical cancer and controllable local treatment, indicating an indication for radiation therapy 5. willing to accept concurrent radiotherapy combined with tislelizumab 6. has measurable disease per response evaluation criteria in solid tumors (recist) 1.1 as assessed by the local investigator 7. has adequate organ function 8. has expected survival time ≥3 months exclusion criteria: 1. has received prior therapy with an anti-programmed cell death receptor 1 (pd-1), or with an agent directed to another stimulatory or co-inhibitory t-cell receptor 2. has a known history of human immunodeficiency virus (hiv) infection，active hepatitis virus infection and active tuberculosis (tb; bacillus tuberculosis) 3. has known active central nervous system (cns) metastases and/or uncontrolled, untreated carcinomatous meningitis with elevated intracranial pressure 4. has received a major surgery within 4 weeks prior to signing informed consent 5. not suitable for radiotherapy 6. reassessment of liver and kidney function and blood routine indexes after radiotherapy did not meet the above criteria 7. did not meet the other requirements for inclusion by the investigator 8. judged unqualified of the enrollment requirements by the researcher according to other conditions
the effect of mentholyptus drops on the palatability of peg-electrolyte solution

Conditions: Colon Cancer

Summary: the investigators aim is to study the efficacy of mentholyptus drops in improving the palatability of peg-electrolyte solution used in bowel cleansing for colonoscopy. the study is a randomized controlled trial which will include patients undergoing elective colonoscopy at the american university of beirut medical center. patients will be randomized into one of two study arms using a computer generated randomization list. patients assigned to the intervention arm will be asked to have candy (halls®) during the whole 2 hours period while drinking the peg solution unlike the control arm patients who will only receive the peg solution. all patients will then be evaluated for the tolerability of the preparation while taking into account the palatability of the solution as main outcome and the remaining volume of the peg solution and side effects as secondary outcomes.


Eligibility criteria:
inclusion criteria: * elective colonoscopy * consent to the study exclusion criteria: * pregnant or lactating women * age less than 18 years * significant gastroparesis * gastric outlet obstruction * ileus * known or suspected bowel obstruction or perforation * phenylketonuria * glucose-6-phosphate dehydrogenase deficiency * severe chronic renal failure (creatinine clearance \<30 ml/minute) * severe congestive heart failure (nyha class iii or iv) * dehydration * severe acute inflammatory disease * compromised swallowing reflex or mental status * uncontrolled hypertension (systolic blood pressure ≥170 mm hg, diastolic blood pressure ≥100 mm hg) * toxic colitis or megacolon * previous colonoscopy within the last 5 years * active inflammatory bowel disease * previous colectomy or partial colectomy

Keywords: peg-electrolyte solution bowel cleansing mentholyptus drops palatability
stopping tsc onset and progression 2b: sirolimus tsc epilepsy prevention study

Conditions: Tuberous Sclerosis Complex; Epilepsy

Summary: this trial is a phase ii randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in tsc infants. this study is supported by research funding from the office of orphan products division (oopd) of the us food and drug administration (fda).

tuberous sclerosis complex (tsc) is caused by genetic mutation in tsc1 or tsc2, resulting in dysregulation of the mechanistic target of rapamycin (mtor) signaling pathway. age at time of seizure onset in tsc infants has been linked to long-term neurodevelopmental outcome in this high-risk population. sirolimus is an mtor inhibitor used to treat many of the symptoms of tsc, including epilepsy. this will be the first study to truly evaluate a targeted, disease-modifying drug therapy for preventing or delaying seizure onset in tsc using a rational, mechanism-based therapeutic approach.

Eligibility criteria:
inclusion criteria: 1. 0-6 months of age at the time of enrollment (subject must be \<7 months of chronological age at time of randomization and treatment initiation). corrected age must be at least 39 weeks (calculated by subtracting the number of weeks born before 40 weeks gestation from the chronological age). 2. has a confirmed diagnosis of tsc based on established clinical or genetic criteria exclusion criteria: 1. prior history of seizures (clinical or electrographic) at the time of enrollment or identified on baseline eeg. 2. has been treated in the past or is currently being treated at the time of enrollment with conventional anticonvulsant medications (aeds), systemic (oral) mtor inhibitors (such as rapamycin, sirolimus, or everolimus), ketogenic-related special diet, or another anti-seizure therapeutic agent, device, or procedure. 3. has taken any other investigational drug as part of another research study, within 30 days prior to the baseline screening visit. 4. has a significant illness or active infection at the time of the baseline screening visit 5. has a history of significant prematurity, defined as gestational age \<30 weeks at the time of delivery, or other significant medical complications at birth or during the neonatal period that other than tsc would convey additional risk of seizures or neurodevelopmental delay (i.e. hie, severe neonatal infection, major surgery, prolonged ventilatory or other life-saving supportive care or procedures). 6. abnormal laboratory values at baseline (i.e., renal function, liver function, or bone marrow production) that are in the opinion of the investigator clinically significant and may jeopardize the safety of the study subject. 7. prior, planned or anticipated neurosurgery within 3 months of the baseline visit 8. has a tsc-associated condition for which mtor treatment is clinically indicated (i.e. sega or aml). 9. subjects who are, in the opinion of the investigator, unable to comply with the requirements of the study.

Keywords: tuberous sclerosis complex tsc epilepsy prevention mtor sirolimus infant
a podcast mind-body program for military caregiver

Conditions: Stress, Psychological

Summary: the purpose of this pilot study is to test the efficacy, feasibility, and acceptability of a brief, online, mind-body wellness program to reduce stress and promote resilience in military caregivers.

the investigators are piloting a brief, online, mind-body program to reduce stress in military caregivers. eligible participants are, 1) at least 18 years old 2) serving as military caregivers and 3) have regular access to a smartphone or computer. the investigators have adapted the smart-3rp into a brief podcast, which we plan to administer daily. participants will be administered questionnaires at baseline, mid-program, and post-program to assess for symptoms of stress, anxiety, and depression. participants will be compensated for completing all measures.

Eligibility criteria:
inclusion criteria: * military caregivers * 18 years of age * regular access to smartphone or computer exclusion criteria: * non-military caregivers * under 18 years of age * no regular access to smartphone or computer

Keywords: stress military caregiver caregiver online podcast mind-body wellness
adjustable continence therapy (act) for the treatment of female sui

Conditions: Urinary Incontinence; Urinary Incontinence,Stress

Summary: a prospective, single arm, non-randomized, multicenter, prospective case-series trial. the purpose of this trial is to demonstrate the safety and effectiveness of using the adjustable continence therapy (act) to provide a clinically relevant improvement in stress urinary incontinence.


Eligibility criteria:
inclusion criteria: 1. female at least 22 years old 2. diagnosed with stress urinary incontinence with primary intrinsic sphincter deficiency 3. provocative pad weight of greater than 11.0 grams 4. candidate for surgical intervention 5. negative urinalysis 6. normal cystourethroscopy 7. failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). note: patients may have failed prior anti-incontinence procedures for sui (e.g., suspension, sling, or urethral bulking agent) 8. willing and able to sign informed consent and comply with trial follow-up requirements exclusion criteria: 1. pregnant or lactating 2. life expectancy of less than 5 years 3. has uncontrolled diabetes as evidenced by hba1c over 6.5% and fasting plasma glucose over 130 mg/dl 4. has auto-immune disease 5. undergoing radiation therapy 6. active urinary tract infection 7. detrusor instability refractory to medication 8. reduced bladder compliance as defined by a cystometrogram 9. significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml 10. has, had, or is suspected of having bladder cancer 11. history of bladder stones 12. urethral stricture evidenced during cystourethroscopy 13. has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia 14. has a diathesis, hemophilia, or a bleeding disorder 15. has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher 16. had prior pelvic radiotherapy 17. had a prior artificial urinary sphincter implanted 18. has a neurogenic condition known to affect bladder/sphincter function

Keywords: urinary incontinence urination disorders urination involuntary urologic diseases lower urinary tract symptoms